MOLECULAR MAKEUP OF HIV-1 ENVELOPE PROTEIN

REFERENCES

• P. J., Maddon, A. G., Dalgleish, J. S., McDougal, P. R., Clapham, R. A., Weiss, R., Axel. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 47: 333–348, 1986
   PubMed Web of Science ®Google Scholar
• M. J., Kowalski, L., Potz, L., Basirpour, T., Dorfman, W. C., Goh, E., Terwilliger, A., Dayton, C., Rosen, W., Haseltine, J., Sodroski. Functional regions of the envelope glycoproteins of human immunodeficiency virus type 1. Science. 237: 1351–1355, 1987
   PubMed Web of Science ®Google Scholar
• V., Veljkovic. A Theoretical Approach to Preselection of Carcinogens and Chemical Carcinogenesis. New York, Gordon & Breach Sci. Pub.,. 1980
   Google Scholar
• F., Chapeville, A. L., Haenni. Chemical Recegnition in Biology. Berlin, Springer-Verlag. 1980
   Google Scholar
• V., Veljkovic, I., Cosic, B., Dimitrijevic, D., Lalovic. Is it possible to analyze DNA and protein sequences by the method of digital signal processing. IEEE Trans. Biomed. Eng.. 32: 337–341, 1985
   PubMed Web of Science ®Google Scholar
• V., Veljkovic, I., Cosic. A novel method of protein analysis for prediction of biological function. Cancer Biochem. Biophys.. 9: 139–148, 1987
   Google Scholar
• I., Cosic. The Resonant Recognition Model of Macromolecular Bioreactivity: Theory and Application. Basel, Birkhauser Verlag. 1997
   Google Scholar
• V., Veljkovic, I., Slavic. General model pseudopotential. Phys. Rev. Lett.. 29: 105–107, 1972, [CROSSREF]
   Web of Science ®Google Scholar
• V., Veljkovic. The dependence of the Fermi energy of the atomic number. Phys. Lett.. A45: 41–42, 1973, [CROSSREF]
   Google Scholar
• V., Veljkovic, R., Metlas. Identification of nanopeptide from HTLV3,LAV and ARV-2 envelope gp120 determining binding to T4 cell surface protein. Cancer Bio chem. Biophys.. 10: 191–196, 1988
   Google Scholar
• P. D., Kwong, R., Wyatt, J., Robinson, R. W., Sweet, J., Sodroski, W. A., Hendrickson. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393: 648–659, 1998, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R., Wyatt, P. D., Kwong, E., Desjardins, R. W., Sweet, J., Robinson, W. A., Hendrickson, J. G., Sodroski. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393: 705–71,, 1998, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• V., Veljkovic, R., Metlas. Sequence similarity between human immunodeficency virus type 1 envelope protein (gp120) and human proteins: A new hypothesis on protective antibody production. Immunol. Lett.. 26: 193–196, 1990, [CROSSREF]
   Google Scholar
• V., Veljkovic, R., Metlas. Identification of immunoglobulin recombination elements in HIV-1 envelope gene. Immunol. Lett.. 31: 11–14, 1991
   Google Scholar
• L. A., Kenter, K. B., Birshtein. Chi, a promoter of generalized recombination in k phage, is present in immunoglobulin genes. Nature. 293: 402–405, 1981, [CROSSREF]
   PubMedGoogle Scholar
• A., Tuter, R., Riblet. Conservation of an immunoglobulin variable-region gene family indicates a specific, noncoding function. Proc. Natl. Acad. Sci. USA. 86: 7460–7464, 1989, [CSA]
   Google Scholar
• S., Tonegawa. Somatic generation of antibody diversity. Nature. 302: 571–581, 1983, [CROSSREF]
   Google Scholar
• H., Sakano, R., Maki, Y., Kurosawa, W., Roeder, S., Tonegawa. Two types of somatic recombination are necessary for the generation of complete immunoglobulin heavy-chain genes. Nature. 286: 676–683, 1980, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D. P., Aplan, P. D., Lombardi, M. A., Ginsberg, J., Cossman, V. L., Bertness, I. R., Kirsch. Disruption of the human SCL locus by “illigitimate” V-(D)-J recombinase activity. Science. 250: 1426–1429, 1990
   PubMed Web of Science ®Google Scholar
• R., Metlas, V., Veljkovic, D. R., Paladini, S., Pongor. Protein and DNA sequence homology between V3 loop of human immunodeficiency virus type 1 envelope protein gp120 and immunoglobulin variable region. Biochem. Biophys. Res. Commun.. 179: 1056–1062, 1991, [CSA], [CROSSREF]
   Google Scholar
• T., Kiber-Emmons, B. A., Jameson, W. J.W., Mortow. The gp120/CD4 interface: Structural, immunological and pathological considerations. Biochem. Biophys. Acta. 989: 281–288, 1989, [CSA]
   Google Scholar
• P. J., Maddon, A. G., Dalgleish, J. S., McDougal, P. R., Clapham, R. A., Weiss, R., Axel. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 47: 333–348, 1986, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. R., Lee, D. D., Ho, M. E., Gurney. Functional interaction and partial homology between human immunodeficiency virus and neuroleukin. Science. 237: 1047–1051, 1987
   PubMed Web of Science ®Google Scholar
• A. R., Kabat, T. T., Wu, M., Reid-Miller. Sequences of Proteins of Immunological Interest. US Department of Health and Human Services, Bethesda, MD, 1990
   Google Scholar
• G. J., LaRosa, J. P., Davide, K., Weinhold, J. A., Waterbury, A. T., Profy, J. A., Lewis, A. J., Langlois, G. R., Dreesman, R. N., Boswell, P., Shadduck. Conserved sequences and structural elements in the HIV-1 principal neutralizing determinant. Science. 249: 932–935, 1990
   PubMed Web of Science ®Google Scholar
• P. Y., Chou, G. D., Fasman. Prediction of protein conformation. Biochemistry. 13: 222–245, 1974, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R., Metlas, V., Skerl, V., Veljkovic, S., Pongor. Further evidence for the relationship of HIV-1 gp120 V3 loops with Ig superfamily members: similarity with the putative CDR3 region of T- cell receptor d-chain. Immunol. Lett.. 47: 25–28, 1995, [CSA], [CROSSREF]
   Google Scholar
• D. F., Lake, S. F., Schluter, E., Wang, R. M., Bernstein, A. B., Edmundson, J. J., Marchalonis. Autoantibodies to the alpha/beta T cell receptor in human immunodeficiency virus infection: Dysregulation and mimicry. Proc. Natl. Acad. Sci. USA. 91: 10849–10853, 1994
   Google Scholar
• A. R., Neurath, N., Strick, P., Taylor, P., Rubinstein, C. E., Stevens. Search for epitope-specific antibody responses to the human immunodeficiency virus (HIV-1) envelope glycoproteins signifying resistence to disease development. AIDS Res. Human Retrovir.. 6: 1183–1192, 1990, [CSA]
   Google Scholar
• T., Mathiesen, P. A., Broliden, J., Rosen, B., Wahren. Mapping of IgG subclass and T cell epitopes on HIV proteins by synthetic peptides. Immunology. 67: 453–459, 1989
   PubMedGoogle Scholar
• P., Kusk, K., Holmback, B. O., Lindhardt, E. F., Hilgaard, T. H., Bugge. Mapping of two new human B-cell epitopes on HIV-1 gp120. AIDS. 6: 1451–1456, 1992
   Google Scholar
• I., Lemasson, V., Housset, B., Calas, C., Devaux. Antigenic analysis of HIV type 1 external envelope (Env) glycoprotein C2 region: Implication for the structure of. Env, AIDS Res. Hum. Retroviruses. 11: 1177–1186, 1995
   Google Scholar
• J. A., Bradac, B. J., Mathieson. An Epitope Map of Immunity to HIV-1: A Roadmap for Vaccine Development, NIAID. NIH, Bethesda, MD 1991
   Google Scholar
• K. J., Sastry, R. B., Arlinghaus. Identification of T cell epitopes without B-cell activity in the first and second conserved regions of the HIV env protein. AIDS. 5: 699–707, 1991
   Google Scholar
• V., Veljkovic, E., Johnson, R., Metlas. Analogy of HIV-1 to oncogenic viruses: possible implication for the pathogenesis of AIDS. Cancer J.. 8: 308–314, 1995
   Google Scholar
• V., Veljkovic, R., Metlas, J., Raspopovic, S., Pongor. Spectral and sequence similarity between vasoactive intestinal peptide and the second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120) Possible consequences on prevention and therapy of AIDS. Biochem. Biophys. Res. Commun.. 189: 705–710, 1992, [CROSSREF]
   Google Scholar
• V., Veljkovic, R., Metlas, D., Vojvodic, Lj., Cavor, A., Dujic, S., Zakhariev, C., Guarnaccia, S., Pongor. Natural autoantibodies crossreact with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120. Biochem. Biophys. Res. Commun.. 196: 1019–1024, 1993, [CROSSREF]
   Google Scholar
• S., Paul, S. I., Said, A., Thompson, D. J., Volle, D. K., Agrawal, H., Foda, S., De la Rocha. Characterization of autoantibodies to VIP in asthma. J. Neuroimmunol. 23: 133–142, 1989, [CROSSREF]
   PubMedGoogle Scholar
• S., Paul, H. P., Erian, S. I., Said. Autoantibody to vasoactive intestinal peptide in human circulation. Biochem. Biophys. Res. Commun.. 130: 479–483, 1985, [CSA], [CROSSREF]
   Google Scholar
• S., Paul, S. I., Said. Human autoantibody to vasoactive intestinal peptide: Increased incidence in muscular exercise. Life Sci.. 43: 1079–1084, 1988, [CROSSREF]
   Google Scholar
• C. B., Pert, J. M., Hill, M. R., Ruff, R. M., Berman, W. G., Robey, L. O., Arthur, F. W., Ruscetti, W. L., Farrar. Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potentially inhibit human immunodeficiency virus receptor binding and T cell infectivity. Proc. Natl. Acad. Sci. USA. 83: 9254–9258, 1986
   Google Scholar
• M., Ruff, P. L., Hallberg, J. M., Hill, C. B., Pert. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment. Lancet. 2: 751, 1987
   Google Scholar
• L. S., Redwine, C. B., Pert, J. D., Rone, R., Nixon, M., Vance, B., Sandler, M. D., Lumpkin, D. J., Dieter, M. R., Ruff. Peptide T blocks gp120/CCR5 chemokine receptormediated chemotaxis. Clin. Immunol.. 93: 124–131, 1999, [CROSSREF]
   PubMedGoogle Scholar
• L., Watterberg, B., Alexius, J., Saaf, A., Sonnenborg, S., Britton, C., Pert. Peptide T in treatment of AIDS. Lancet. 1: 159, 1987, [CROSSREF]
   Google Scholar
• T. P., Bridge, P., Heseltine, E. S., Parker, E., Eaton, L. J., Ingraham, M., Gill, M. R., Ruff, C. B., Pert, F. K., Goodwin. Improvements in AIDS patients on peptide T. Lancet. 2: 226–227, 1989
   Google Scholar
• J. A., Marcusson, D., Lazenga, C. B., Pert, M. R., Ruff, K. G., Sundquist, L., Wetterberg. Peptide T and psoriasis. Acta Derm Venereol Suppl (Stockh).,. 146: 117–121, 1989
   Google Scholar
• M. R., Ruff, C., Smith, T., Kingan, H., Jaffe, P., Heseltine, M. A., Gill, K., Mayer, C. B., Pert, T. P., Bridge. Pharmacokinetics of peptide T in patients with acquired immunodeficiency syndrome (AIDS). Prog. Neuropsychopharmacol. Biol. Psychiatry. 15: 791–801, 1991, [CSA], [CROSSREF]
   Google Scholar
• V. L., Villemagne, R. L., Phillips, X., Liu, S. F., Gilson, R. F., Dannals, D. F., Wong, P. J., Harris, M., Ruff, C. B., Pert, P., Bridge, E. D., London. Peptide T and glucose metabolism in AIDS dementia complex. J. Nucl. Med.. 37: 1177–1180, 1996
   Google Scholar
• D. E., Brenneman, G. L., Westbrook, S. P., Fitzgerald, D. L., Ennist, K. L., Elkins, M. R., Ruff, C. B., Pert. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature. 335: 639–642, 1988, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. E., Mulroney, K., McDonnell, C. B., Pert, M. R., Ruff, W. K., Samson, M. D., Lumpkin. HIV gp120 inhibits the somatotropic axis: A possible GHRH receptor mechanism ror the pathogenesis of AIDS wasting. Proc. Natl. Acad. Sci USA. 95: 1927–1931, 1988
   Google Scholar
• T. R., Kosten, M. I., Rosen, T. L., McMahon, T. P., Bridge, S. S., O'Malley, R., Pearsall, P. G., O'Connor. Treatment of early AIDS dementia in intravenous drug user: High versus low dose peptide T. Am. J. Drug Alcohol Abuse. 23: 543–553, 1997, [CSA]
   PubMed Web of Science ®Google Scholar
• J. M., Hill, R. F., Mervis, R., Avidor, T. W., Moody, D. E., Brenneman. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res.. 603: 222–233, 1993, [CROSSREF]
   Google Scholar
• T., Smart. Peptide T for cognitive impairment. GMHC Treat Issues. 9: 15, 1995, [CSA]
   Google Scholar
• P. N., Heseltine, K., Goodkin, J. H., Atkinson, B., Vitiello, J., Rochon, R. K., Heaton, E. M., Eaton, F. L., Wilkie, E., Sobel, S. J., Brown, D., Feaster, L., Schneider, W. L., Goldschmidts, E. S., Stover. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch. Neurol.. 55: 41–51, 1998, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J., Sodroski, M., Kowalski, T., Dorfman, L., Basiripour, C., Rosen, W., Haseltine. HIV envelope-CD4 interaction not inhibited by synthetic octapeptides. Lancet. 1: 1428–1429, 1987
   Google Scholar
• M., Delafuente, M., Delgado, R. P., Gomeriz. VIP modulation of immune cell functions. Adv. Neuroimmunol. 6: 75, 1996, [CSA]
   Google Scholar
• H. F., Wang, Z., Xin, H., Tang, D., Ganea. Vasoactive intestinal peptide inhibits IL-4 production in murine T cells by a post-transcriptional mechanism. J. Immunol.. 156: 3243, 1996
   Google Scholar
• D., Pozo, M., Delgado, C., Martinez, J. M., Guerrero, J., Leceta, R. P., Gomariz, J. R., Calvo. Immunobiology of vasoactive intestinal peptide (VIP). Immunol. Today. 21: 7–11, 2000, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Y., Yiangou, R., Serrano, S. R., Bloom, J., Pena, H., Festenstein. Effects of prepro-vasoactive intestinal peptide-derived peptides on the murine immune response. J. Neuroimmunol. 29: 65–72, 1990
   Google Scholar
• D. A., Nio, R. N., Moylan, J. K., Roche. Modulation of T lymphocyte function by neuropeptides. Evidence for their role as local immunoregulatory elements. J. Immunol.. 150: 5281–5288, 1993
   PubMed Web of Science ®Google Scholar
• D., Ganea, L., Sun. Vasoactive intestinal peptide downregulates the expression of IL-2 but not of IFN gamma from stimulated murine T lymphocytes. J. Neuroimmunol. 47: 147–156, 1993, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L., Sun, D., Ganea. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J. Neuroimmunol. 48: 59–65, 1993, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Z., Xin, H., Tang, D., Ganea. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via the TCR/CD3 complex. J. Neuroimmunol. 54: 59–68, 1994, [CROSSREF]
   PubMedGoogle Scholar
• S., Teresi, F., Boudard, M., Bastide. Effect of calcitonin gene-related peptide and vasoactive intestinal peptide on murine CD4 and CD8 T cell proliferation. Immunol. Lett.. 50: 105–113, 1996, [CSA], [CROSSREF]
   Google Scholar
• M., Delgado, J., Leceta, R. P., Gomariz, D., Ganea. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J. Immunol.. 163: 3629–3635, 1999
   PubMed Web of Science ®Google Scholar
• H., Kimata, M., Fujimoto. Induction of IgA1 and IgA2 production in immature human fetal B cells and pre-B cells by vasoactive intestinal peptide. Blood. 85: 2098–2104, 1995, [CSA]
   PubMedGoogle Scholar
• D., Ganea. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 6: 61–67, 1996, [CSA]
   PubMed Web of Science ®Google Scholar
• H., Kimata. Vasoactive intestinal peptide differentially modulates human immunoglobulin production. Adv.. Neuroimmunol. 6: 107–114, 1996, [CSA]
   Google Scholar
• M., Delgado, E. J., Munoz-Elias, R. P., Gomariz, D., Ganea. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol.. 162: 1707–1716, 1999
   PubMed Web of Science ®Google Scholar
• M., Delgado, E. J., Munoz-Elias, R. P., Gomariz, D., Ganea. VIP. and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J. Neuroimmunol. 96: 167–181, 1999, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Y., Wang, X., Jiang, I., Gozes, M., Fridkin, D. E., Brenneman, D., Ganea. Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms, Regul.. Pept.. 84: 55–67, 1999, [CROSSREF]
   Google Scholar
• C., Azzari, M. E., Rossi, M., Resti, A. L., Caldini, S., Ciappi, A., Vierucci. VIP restores natural killer cell activity depressed by hepatitis B surface antigen, Viral.. Immunol.. 5: 195–200, 1992
   Google Scholar
• M. C., Sirianni, B., Annibale, F., Tagliaferri, S., Fais, S., De Luca, F., Pallone, G., Delle Fave, F., Aiuti. Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family VIP glucagon and GHRF specifically inhibit NK activity, Regul.. Pept.. 38: 79–87, 1992, [CROSSREF]
   Google Scholar
• M., Rola-Pleszczynski, D., Boldue, S., St-Pierre. The effects of vasoactive intestinal peptide on human natural killer cell function. J. Immunol.. 135–146, 2569. 1985
   Google Scholar
• P. A., Drew, D. J., Shearman. Vaso-active intestinal peptide: a neurotransmitter which reduces human NK cell activity and increases Ig synthesis. Aust. J. Exp. Biol. Med. Sci.. 63: 313–318, 1985
   PubMedGoogle Scholar
• M., Peruzzi, C., Azzari, M. E., Rossi, M., De Martino, A., Vierucci. Inhibition of natural killer cell cytotoxicity and interferon gamma production by the envelope protein of HIV and prevention by vasoactive intestinal peptide. AIDS Res. Human Retrovir.. 16: 1067–1073, 2000, [CSA], [CROSSREF]
   Google Scholar
• A., Bairoch, B., Boeckmann. The SWISS-PROT protein sequence data bank. Nucleic Acids Res. 20, (Suppl.). 2019–2027, 1922
   Google Scholar
• R., Metlas, V., Skerl, A., Colombatti, S., Pongor, V., Veljkovic. Reactivity of AIDS patient seara with a peptide derived from HIV type 1NY5 glycoprotein 120 V3 loop and consensus sequence of collagens. AIDS Res. Hum. Retrovir.. 10: 1425–1426, 1994, [CSA]
   Google Scholar
• M. D., Grant, M. S., Weaver, C., Tsoukas. Distribution of antibodies against denaturated collagen in AIDS risk group and homosexual AIDS patients suggesting a link between autoimmunity and the immunopathogenesis of AIDS. J. Immunol.. 144: 1241–1250, 1990
   Google Scholar
• A. E., Kabat, T. T., Wu, H. M., Perry. Sequences of proteins of immunological interest. Release 5.0. 1992
   Google Scholar
• R., Metlas, V., Skerl, V., Veljkovic, A., Colombatti, S., Pongor. Immunoglobulin like domain of HIV-1envelope glycoprotein gp120 encodes putative internal image of some common human proteins. Viral Immunol.. 7: 215–219, 1995, [CSA]
   Google Scholar
• IntelliGenetics—Molecular Biology Software System. Release 5.4. 1991, [CSA]
   Google Scholar
• F., Myers. Human Retroviruses and AIDS Database. Los Alamos, NM, Los Alamos National Laboratory. 1990
   Google Scholar
• E. M., Rakowicz-Szulczynska, M., Markowski, A., Mackiewicz, A., Karczewska, W., Snyder, D. G., McIntosh, M., Kapcinska, M. L., Smith. New protein and PCR marker RAK for diagnosis, prognosis and surgery guidance for breast cancer. Cancer Lett.. 112: 93, 1997, [CSA], [CROSSREF]
   Google Scholar
• E. M., Rakowicz-Szulczynska, B., Jackson, W., Snyder. Prostate, breast and gynecological cancer markers RAK with homology to HIV-1. Cancer Lett.. 124: 213–223, 1998, [CSA], [CROSSREF]
   Google Scholar
• E. M., Rakowicz-Szulczynska, B., Jackson, A. M., Szulczynska, M., Smith. Human immunodeficiency virus type 1-like DNA sequences and immunoreactive viral particles with unique association with breast cancer. Clin. Diagnost. Lab. Immunol.. 5: 645–650, 1998, [CSA]
   Google Scholar
• E. M., Rakowicz-Szulczynska, D. G., McIntosh, M., Smith. Giant syncytia and virus-like particles in ovarian carcinoma cell isolated from ascites fluid. Clin. Diagnost Lab. Immunol.. 6: 115–120, 1999, [CSA]
   Google Scholar
• E. M., Rakowicz-Szulczynska. Relevance of the viral RAK alpha gene in diagnosis of malignant versus nonmalignant tumors of the ovary and uterus. Clin. Diagn. Lab. Immunol.. 7: 360–365, 2000, [CSA], [CROSSREF]
   Google Scholar
• E. M., Rakowicz-Szulczynska, D. G., McIntosh, M. J., Perryl, M. J., Smith. Mechanisms of cancer growth promotion by HIV-1 neutralizing antibodies. Cancer J. 8: 143–147, 1995
   Google Scholar
• E. M., Rakowicz-Szulczynska. Detection and treatment of breast and gynecological cancer. U.S. Patent, 1-st., No., 5,939,277. 1996
   Google Scholar
• E. M., Rakowicz-Szulczynska, M. J., Perry, D. G., McIntosh. et al.. Mechanisms of cancer growth promotion by HIV-1 neutralizing antibodies. Cancer J. 8: 143–149, 1995
   Google Scholar
• P. W.S., Szawlowski, T., Hanke, R. E., Randall. Sequence homology between HIV-1 gp120 and the apoptosis mediating protein Fas. AIDS. 7: 1018–1019, 1993
   Google Scholar
• P., Kusk, K., Holmback, B. O., Lindhart. Mapping of two new human B-cell epi-topes in HIV-1 gp120. AIDS. 6: 1451–1456, 1992
   Google Scholar
• Z., Moukrim, A., Achour. Cytotoxic T lymphocytes specific for the synthetic VEINCTR peptide, a sequence found within the Fas molecule and env gp120 in the blood of HIV-1 seropositive individuals. Cell Mol. Biol.. 41: 439–444, 1995, [CSA]
   Google Scholar
• F., Silvestris, S., Nagata, P., Cafforio, N., Silvestris, F., Dammacco. Cross-linking of Fas by antibodies to a peculiar domain of gp120 V3 loop can enhance T cell apoptosis in HIV-1-infected patients. J. Exp. Med. 184: 2287–2300, 1996, [CROSSREF]
   Google Scholar
• M., Boirivant, M., Viora, L., Giordani, A. L., Luzzati, A. M., Pronio, C., Montesani, O., Pugliese. HIV-1 gp120 accelerates Fas-mediated activation-induced human lamina propria T cell apoptosis. J. Clin. Immunol.. 18: 39–47, 1998, [CROSSREF]
   Google Scholar
• D. W., Archibald, G. A., Cole. In vitro inhibition of HIV-1 infectivity by human salivas. AIDS Res. Human Retrovir.. 6: 1425–1429, 1990, [CSA]
   PubMed Web of Science ®Google Scholar
• R., Crombie, R. L., Silverstein, C., MacLowet, S. F., Pearce, R. L., Nachman, J., Laurence. Identification of aCD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120:Relationship to HIV-1-specific inhibitory factors in human saliva. J. Exp. Med. 187: 25–35, 1998, [CROSSREF]
   Google Scholar
• R., Mark, M. R., Lee, D. D., Ho, M. E., Gurney. Functional interaction and partial homology between human immunodeficency virus and neuroleukin. Science. 237: 1047–1051, 1987
   Google Scholar
• D. E., Brenneman, G. L., Westbrook, S. P., Fitzgerald, D. L., Ennist, K. L., Elkins, C. B., Pert. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature. 335: 639–642, 1988, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L., Berberian, L., Goodglick, T. J., Kipps, J., Braun. Immunoglobulin VH3 gene products: Natural ligands for HIV-1 gp120. Science. 261: 1588–1591, 1993
   PubMed Web of Science ®Google Scholar
• G. J., Silverman. Superantigens and the spectrum of unconventional B-cell antigens. The Immunologist. 2: 51–60, 1994
   Google Scholar
• L., Goodglick, N., Zevit, M. S., Neshat, J., Braun. Mapping the Ig superantigen-binding site of HIV-1 gp120. J. Immunol.. 155: 5151–5159, 1995
   PubMed Web of Science ®Google Scholar
• S., Karray, M., Zoualli. Identification of the B cell superantigen-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA. 94: 1356, 1997
   Google Scholar
• L., Brown, B. E., Souberbielle, J. B., Marriott, M., Westby, U., Desselberger, T., Kaye, M. L., Gougeon, A., Dalgleish. The conserved carboxy terminal region of HIV-1 gp120 is recognized by seronegative HIV-exposed people. AIDS. 13: 2515–2521, 1999, [CROSSREF]
   Google Scholar
• C., De Santis, P., Robbioni, R., Longhi, L., Lopalco, A. G., Siccardi, A., Beretta, N. J., Roberts, Jr. Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chain induced by receptor of HIV-1-derived envelope vaccines. J. Infect. Dis. 168: 1396–1403, 1993
   Google Scholar
• S., Karpatkin, M., Nardi. Autoimmune anti-HIV-1 gp120 antibody with antiidiotype-like activity in sera and immune complexes of HIV-1-related immunological thrombocytopenia. J. Clin. Invest. 89: 356–364, 1992, [CSA]
   PubMed Web of Science ®Google Scholar
• A., Bettaieb, E., Oksenhendler, N., Duedari, P., Bierling. Cross-reactive anti-bodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Clin. Exp. Immunol.. 103: 19–23, 1996, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• B., Solder, P., Marschang, H., Wachter, M. P., Dierich, S., Nayyar, I. V., Lewin, D. R., Stanworth. Anti-viral antibodies in HIV (HTLV-III) infection possess Autoantibody activity against a CH1 domain determinant in human IgG: Possible immunological consequences. Immunol. Let. 23: 9–19, 1989, [CSA], [CROSSREF]
   Google Scholar
• C., Susal, I. V., Lewin, D. R., Stanworth, P., Terness, V., Daniel, H. H., Oberg, A., Huth-Kuhne, R., Zimmermann, G., Opelc. Anti-IgG autoantibodies in HIV-infected hemophilia patients. Vox Sang. 62: 224–229, 1992
   PubMed Web of Science ®Google Scholar
• C., Susal, M., Kropelin, V., Daniel, G., Opelz. Molecular mimicry between HIV-1 and antigen receptor molecules: A clue to the pathogenesis of AIDS. Vox Sang. 65: 10–17, 1993
   Google Scholar
• J., Homsy, M., Mayer, J. A., Levy. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV- infected individuals. J. Virol. 64: 1437–1445, 1990, [CSA]
   Google Scholar
• W. E., Robinson, Jr., T., Kawamura, M. K., Gorny, D., Lake, J. Y., Xu, Y., Matsumoto, T., Sugano, Y., Masuho, W. M., Mitchell, E., Hersh, S., Zolla-Pazner. Human monoclonal antibodies to the human immunodeficency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc. Natl. Acad. Sci USA. 87: 3185–3189, 1990
   Google Scholar
• S., Jiang, K., Lin, A. R., Neurath. Enhancement of human immunodeficiency virus type 1 (HIV-1) infection by antisera to peptides from the envelope glycoproteins gp120/41. J. Exp. Med.. 174: 1557–1563, 1991
   PubMedGoogle Scholar
• S., Jiang, A. R., Neurath. Potential risk of eliciting antibodies enhancing HIV-1 infection of monocytic cells by vaccination with V3 loops of unmatched HIV-1 isolates. AIDS. 6: 331–332, 1992
   Google Scholar
• R. H., Haubrich, A., Takeda, W., Koff, G., Smith, F. A., Ennis. Studies of antibodydependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine. J. Infect. Dis. 165: 545–548, 1992
   Google Scholar
• G., Faust. Enhancing antibodies in HIV infection, Parasitology. 115, (Suppl.): S127-S140. 1997
   Google Scholar
• P., Auewarakul, S., Louisirirotchanakul, R., Sutthent, T., Taechowisan, C., Kanoksinsombat, C., Wasi. Analysis of neutralizing and enhancing antibodies to human immunodeficency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand. Viral Immunol.. 9: 175–185, 1996, [CSA]
   Google Scholar
• L. A., Cavacini, A., Wisnewski, J. E., Peterson, D., Montefiori, C., Emes, M., Duval, G., Kingsbury, A., Wang, D., Scadden, M. R., Posner. A human anti-HIV autoantibodies enhances EBV transformation and HIV infection. Clin. Immunol.. 93: 263–273, 1999, [CROSSREF]
   Google Scholar